$0.525100
-0.02-3.83%
At Close: -
$0.527400
0.00230.44%
After Hours: 6:23 PM EDT
15 minutes delayed
Comments
Loading...
Spruce Biosciences
SPRBNASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Spruce Biosciences (NASDAQ:SPRB) Stock, Analyst Ratings, Price Targets, Forecasts
Spruce Biosciences Inc has a consensus price target of $4.29 based on the ratings of 11 analysts. The high is $9 issued by SVB Leerink on September 8, 2023. The low is $2 issued by RBC Capital on March 14, 2024. The 3 most-recent analyst ratings were released by Oppenheimer, RBC Capital, and JMP Securities on June 13, 2024, March 14, 2024, and March 14, 2024, respectively. With an average price target of $2.67 between Oppenheimer, RBC Capital, and JMP Securities, there's an implied 405.63% upside for Spruce Biosciences Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Oppenheimer
RBC Capital
JMP Securities
Leerink Partners
SVB Leerink
1calculated from analyst ratings
Analyst Ratings for Spruce Biosciences
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/13/2024 | Buy Now | 468.83% | Oppenheimer | Hartaj Singh | $4 → $3 | Maintains | Outperform | Get Alert |
| 06/05/2024 | Buy Now | — | HC Wainwright & Co. | Raghuram Selvaraju | — | Reiterates | → Neutral | Get Alert |
| 05/14/2024 | Buy Now | — | HC Wainwright & Co. | Raghuram Selvaraju | — | Reiterates | → Neutral | Get Alert |
| 03/14/2024 | Buy Now | 279.22% | RBC Capital | Gregory Renza | $9 → $2 | Downgrade | Outperform → Sector Perform | Get Alert |
| 03/14/2024 | Buy Now | 468.83% | JMP Securities | Jonathan Wolleben | $8 → $3 | Maintains | Market Outperform | Get Alert |
| 03/14/2024 | Buy Now | — | HC Wainwright & Co. | Raghuram Selvaraju | — | Downgrade | Buy → Neutral | Get Alert |
| 03/14/2024 | Buy Now | 279.22% | Leerink Partners | Joseph Schwartz | $9 → $2 | Downgrade | Outperform → Market Perform | Get Alert |
| 03/14/2024 | Buy Now | — | Ladenburg Thalmann | Aydin Huseynov | — | Downgrade | Buy → Neutral | Get Alert |
| 03/14/2024 | Buy Now | — | Guggenheim | Evan Wang | — | Downgrade | Buy → Neutral | Get Alert |
| 03/05/2024 | Buy Now | 1606.48% | RBC Capital | Gregory Renza | → $9 | Reiterates | Outperform → Outperform | Get Alert |
| 02/26/2024 | Buy Now | 1606.48% | RBC Capital | Gregory Renza | $8 → $9 | Maintains | Outperform | Get Alert |
| 02/21/2024 | Buy Now | 1796.09% | Guggenheim | Evan Wang | → $10 | Initiates | → Buy | Get Alert |
| 11/20/2023 | Buy Now | 1796.09% | HC Wainwright & Co. | Raghuram Selvaraju | → $10 | Reiterates | Buy → Buy | Get Alert |
| 09/13/2023 | Buy Now | 1416.88% | RBC Capital | Gregory Renza | → $8 | Reiterates | Outperform → Outperform | Get Alert |
| 09/13/2023 | Buy Now | 1796.09% | HC Wainwright & Co. | Raghuram Selvaraju | → $10 | Reiterates | Buy → Buy | Get Alert |
| 09/08/2023 | Buy Now | 1606.48% | SVB Leerink | Joseph Schwartz | $3 → $9 | Upgrade | Market Perform → Outperform | Get Alert |
| 08/18/2023 | Buy Now | 1227.27% | Oppenheimer | Hartaj Singh | $8 → $7 | Maintains | Outperform | Get Alert |
| 08/18/2023 | Buy Now | 1796.09% | HC Wainwright & Co. | Raghuram Selvaraju | → $10 | Reiterates | Buy → Buy | Get Alert |
| 08/16/2023 | Buy Now | 1416.88% | JMP Securities | Jonathan Wolleben | $7 → $8 | Maintains | Outperform | Get Alert |
| 08/15/2023 | Buy Now | 1416.88% | RBC Capital | Gregory Renza | → $8 | Reiterates | Outperform → Outperform | Get Alert |
| 06/13/2023 | Buy Now | 1796.09% | HC Wainwright & Co. | Raghuram Selvaraju | → $10 | Reiterates | Buy → Buy | Get Alert |
| 05/23/2023 | Buy Now | 1416.88% | Oppenheimer | Hartaj Singh | → $8 | Reiterates | Outperform → Outperform | Get Alert |
| 05/16/2023 | Buy Now | 1416.88% | RBC Capital | Gregory Renza | → $8 | Reiterates | Outperform → Outperform | Get Alert |
| 05/16/2023 | Buy Now | 1227.27% | JMP Securities | Jonathan Wolleben | → $7 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 05/16/2023 | Buy Now | 658.44% | Credit Suisse | Tiago Fauth | → $4 | Reiterates | Outperform → Outperform | Get Alert |
| 03/23/2023 | Buy Now | 1796.09% | HC Wainwright & Co. | Raghuram Selvaraju | $20 → $10 | Maintains | Buy | Get Alert |
| 03/20/2023 | Buy Now | 1416.88% | RBC Capital | Gregory Renza | → $8 | Reiterates | → Outperform | Get Alert |
| 03/17/2023 | Buy Now | 1227.27% | JMP Securities | Jonathan Wolleben | → $7 | Maintains | Market Outperform | Get Alert |
| 03/17/2023 | Buy Now | 658.44% | Credit Suisse | Tiago Fauth | → $4 | Reiterates | → Outperform | Get Alert |
| 02/13/2023 | Buy Now | 1416.88% | RBC Capital | Gregory Renza | $9 → $8 | Maintains | Outperform | Get Alert |
| 01/08/2023 | Buy Now | 1416.88% | JMP Securities | Jonathan Wolleben | $8 → $8 | Maintains | Outperform | Get Alert |
| 11/17/2022 | Buy Now | 1416.88% | Oppenheimer | Hartaj Singh | $13 → $8 | Maintains | Outperform | Get Alert |
| 11/16/2022 | Buy Now | 1416.88% | JMP Securities | Jonathan Wolleben | → $8 | Initiates | → Market Outperform | Get Alert |
| 03/16/2022 | Buy Now | 468.83% | SVB Leerink | Joseph Schwartz | $5 → $3 | Maintains | Market Perform | Get Alert |
| 03/15/2022 | Buy Now | 1606.48% | RBC Capital | Gregory Renza | $13 → $9 | Maintains | Outperform | Get Alert |
| 03/08/2022 | Buy Now | 1037.66% | Ladenburg Thalmann | Aydin Huseynov | → $6 | Initiates | → Buy | Get Alert |
| 12/17/2021 | Buy Now | 2744.14% | Oppenheimer | Hartaj Singh | — | Initiates | → Outperform | Get Alert |
| 12/10/2021 | Buy Now | 1227.27% | Benchmark | Aydin Huseynov | — | Initiates | → Speculative Buy | Get Alert |
| 11/23/2021 | Buy Now | — | Cowen & Co. | Ritu Baral | — | Downgrade | Outperform → Market Perform | Get Alert |
| 11/16/2021 | Buy Now | 3692.19% | HC Wainwright & Co. | Raghuram Selvaraju | — | Maintains | Buy | Get Alert |
| 11/16/2021 | Buy Now | 1037.66% | Credit Suisse | Tiago Fauth | — | Maintains | Outperform | Get Alert |
| 11/16/2021 | Buy Now | 848.05% | SVB Leerink | Joseph Schwartz | — | Downgrade | Outperform → Market Perform | Get Alert |
FAQ
What is the target price for Spruce Biosciences (SPRB) stock?
The latest price target for Spruce Biosciences (NASDAQ:SPRB) was reported by Oppenheimer on June 13, 2024. The analyst firm set a price target for $3.00 expecting SPRB to rise to within 12 months (a possible 468.83% upside). 20 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Spruce Biosciences (SPRB)?
The latest analyst rating for Spruce Biosciences (NASDAQ:SPRB) was provided by Oppenheimer, and Spruce Biosciences maintained their outperform rating.
When was the last upgrade for Spruce Biosciences (SPRB)?
The last upgrade for Spruce Biosciences Inc happened on September 8, 2023 when SVB Leerink raised their price target to $9. SVB Leerink previously had a market perform for Spruce Biosciences Inc.
When was the last downgrade for Spruce Biosciences (SPRB)?
The last downgrade for Spruce Biosciences Inc happened on March 14, 2024 when RBC Capital changed their price target from $9 to $2 for Spruce Biosciences Inc.
When is the next analyst rating going to be posted or updated for Spruce Biosciences (SPRB)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Spruce Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Spruce Biosciences was filed on June 13, 2024 so you should expect the next rating to be made available sometime around June 13, 2025.
Is the Analyst Rating Spruce Biosciences (SPRB) correct?
While ratings are subjective and will change, the latest Spruce Biosciences (SPRB) rating was a maintained with a price target of $4.00 to $3.00. The current price Spruce Biosciences (SPRB) is trading at is $0.53, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.